GEP20032969B - Sertraline Oral Concentrate - Google Patents

Sertraline Oral Concentrate

Info

Publication number
GEP20032969B
GEP20032969B GEAP19995852A GEAP1999005852A GEP20032969B GE P20032969 B GEP20032969 B GE P20032969B GE AP19995852 A GEAP19995852 A GE AP19995852A GE AP1999005852 A GEAP1999005852 A GE AP1999005852A GE P20032969 B GEP20032969 B GE P20032969B
Authority
GE
Georgia
Prior art keywords
concentrate
pharmaceutically acceptable
provides
present
sertraline
Prior art date
Application number
GEAP19995852A
Other languages
English (en)
Inventor
Willard Mckowan Welch
Nancy Jane Harper
Gautam Ramchandra Ranade
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22298286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20032969(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GEP20032969B publication Critical patent/GEP20032969B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GEAP19995852A 1998-10-13 1999-09-22 Sertraline Oral Concentrate GEP20032969B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10402498P 1998-10-13 1998-10-13

Publications (1)

Publication Number Publication Date
GEP20032969B true GEP20032969B (en) 2003-05-27

Family

ID=22298286

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19995852A GEP20032969B (en) 1998-10-13 1999-09-22 Sertraline Oral Concentrate

Country Status (46)

Country Link
EP (1) EP1121107B1 (fr)
JP (1) JP3792514B2 (fr)
KR (1) KR100417200B1 (fr)
CN (1) CN1184962C (fr)
AP (1) AP2001002119A0 (fr)
AR (1) AR014082A1 (fr)
AT (1) ATE254453T1 (fr)
AU (1) AU766202B2 (fr)
BG (1) BG65085B1 (fr)
BR (1) BR9914418A (fr)
CA (1) CA2346335C (fr)
CO (1) CO5150213A1 (fr)
CZ (1) CZ20011286A3 (fr)
DE (1) DE69912978T2 (fr)
DK (1) DK1121107T3 (fr)
DZ (1) DZ2913A1 (fr)
EA (1) EA003990B1 (fr)
EE (1) EE04868B1 (fr)
EG (1) EG23818A (fr)
ES (1) ES2209490T3 (fr)
GC (1) GC0000175A (fr)
GE (1) GEP20032969B (fr)
GT (1) GT199900171A (fr)
HK (1) HK1040199B (fr)
HR (1) HRP20010263B1 (fr)
HU (1) HUP0104470A3 (fr)
ID (1) ID29845A (fr)
IS (1) IS2239B (fr)
MA (1) MA26698A1 (fr)
MY (1) MY122477A (fr)
NO (1) NO20011829L (fr)
NZ (1) NZ510756A (fr)
OA (1) OA11662A (fr)
PA (1) PA8483301A1 (fr)
PE (1) PE20001108A1 (fr)
PL (1) PL348119A1 (fr)
PT (1) PT1121107E (fr)
PY (1) PY990106A (fr)
SK (1) SK4582001A3 (fr)
TN (1) TNSN99190A1 (fr)
TR (1) TR200101090T2 (fr)
TW (1) TWI228043B (fr)
UA (1) UA72743C2 (fr)
WO (1) WO2000021521A2 (fr)
YU (1) YU26401A (fr)
ZA (1) ZA200102900B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1671628B1 (fr) 1999-09-03 2012-10-03 APBI Holdings, LLC Inhibiteurs de réabsorption de sérotonine à action rapide pour le traitement des dysfonctions sexuelles
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2004065348A1 (fr) 2003-01-23 2004-08-05 Pfizer Products Inc. Sels pharmaceutiquement acceptables de sertraline et compositions pharmaceutiques correspondantes
WO2005000786A1 (fr) * 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Compositions de sertraline
WO2005034910A1 (fr) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Compositions pharmaceutiques liquides de sertraline a administration orale
WO2007052152A2 (fr) * 2005-11-07 2007-05-10 Aurobindo Pharma Limited Concentré oral d'un antidépresseur
WO2008112641A2 (fr) * 2007-03-09 2008-09-18 New York University Procédés et compositions pour le traitement de la dysrythmie thalamocorticale
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114225038A (zh) * 2021-06-02 2022-03-25 青海春天药用资源科技股份有限公司 酒精和凉味剂组合物在调节性功能、护血管、肝细胞再生、抗肿瘤、提高免疫及睡眠的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
CA2143070C (fr) * 1994-02-22 2001-12-18 Pankaj Modi Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
SE508372C2 (sv) * 1995-02-13 1998-09-28 Kjell Lindstroem Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar
ATE235237T1 (de) * 1995-07-17 2003-04-15 Pfizer Sertralin zur behandlung von post-myocard-infarkt-patienten
EP0980241B1 (fr) * 1997-07-01 2003-12-17 Pfizer Products Inc. Formes posologiques de sertraline, en solution et encapsulees dans de la gelatine

Also Published As

Publication number Publication date
TNSN99190A1 (fr) 2005-11-10
CA2346335A1 (fr) 2000-04-20
MA26698A1 (fr) 2004-12-20
PE20001108A1 (es) 2000-10-26
NO20011829L (no) 2001-06-05
AR014082A1 (es) 2001-01-31
CN1184962C (zh) 2005-01-19
TWI228043B (en) 2005-02-21
CO5150213A1 (es) 2002-04-29
EE200100221A (et) 2002-08-15
UA72743C2 (en) 2005-04-15
KR20010080096A (ko) 2001-08-22
KR100417200B1 (ko) 2004-02-05
JP3792514B2 (ja) 2006-07-05
TR200101090T2 (tr) 2001-12-21
ZA200102900B (en) 2002-05-29
HUP0104470A2 (en) 2002-08-28
EA003990B1 (ru) 2003-12-25
PA8483301A1 (es) 2000-09-29
PY990106A (es) 2007-11-01
PT1121107E (pt) 2004-02-27
MY122477A (en) 2006-04-29
HUP0104470A3 (en) 2003-12-29
NO20011829D0 (no) 2001-04-10
PL348119A1 (en) 2002-05-06
WO2000021521A3 (fr) 2000-07-20
GT199900171A (es) 2001-03-28
CN1323202A (zh) 2001-11-21
ID29845A (id) 2001-10-18
CZ20011286A3 (cs) 2001-09-12
DE69912978T2 (de) 2004-04-22
HK1040199A1 (en) 2002-05-31
IS2239B (is) 2007-05-15
AU766202B2 (en) 2003-10-09
EP1121107B1 (fr) 2003-11-19
WO2000021521A2 (fr) 2000-04-20
GC0000175A (en) 2006-03-29
BG65085B1 (bg) 2007-02-28
IS5906A (is) 2001-03-23
EE04868B1 (et) 2007-08-15
SK4582001A3 (en) 2002-02-05
EG23818A (en) 2007-09-19
HRP20010263A2 (en) 2002-06-30
EP1121107A2 (fr) 2001-08-08
HK1040199B (zh) 2005-05-27
DE69912978D1 (de) 2003-12-24
ATE254453T1 (de) 2003-12-15
NZ510756A (en) 2003-05-30
BG105434A (bg) 2001-12-29
AU5643699A (en) 2000-05-01
EA200100285A1 (ru) 2001-10-22
JP2002527385A (ja) 2002-08-27
ES2209490T3 (es) 2004-06-16
DK1121107T3 (da) 2004-02-23
HRP20010263B1 (en) 2005-04-30
DZ2913A1 (fr) 2004-03-01
YU26401A (sh) 2005-07-19
AP2001002119A0 (en) 2001-03-22
OA11662A (en) 2004-12-08
BR9914418A (pt) 2001-06-26
CA2346335C (fr) 2006-04-18

Similar Documents

Publication Publication Date Title
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
WO2005065069A3 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
CA2427227A1 (fr) Compose de lactam
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
GEP20032958B (en) Adenosine Derivatives
MY106938A (en) Method of treating premature ejaculation using sertraline
IL108234A0 (en) Pharmaceutical composition containing galanthamine
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
KR970061244A (ko) 치매 치료용 약학 조성물
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
GEP20032969B (en) Sertraline Oral Concentrate
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
DE69922017D1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
MY124465A (en) Reduction of infarct volume using citicoline
BR0111002A (pt) Combinação de secretagogos do hormÈnio do crescimento e antidepressivos
WO2001068076A8 (fr) Enantiomere en d de la dfmo et ses procedes d'utilisation
GEP20043377B (en) Pharmaceutical Complex
EP0768083A3 (fr) L'utilisation de la sertraline dans le traitement des patients post-infarction myocardique
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
ECSP993166A (es) Concentrado oral de sertralina
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan